Kymanox, a Morrisville, North Carolina-headquartered life sciences consulting and professional services firm with offices in King of Prussia, Pennsylvania and Bern, Switzerland, announced on October 5, 2026 the launch of KymaBridge™. The searchable online intelligence platform helps pharmaceutical and biotechnology companies identify, compare, and evaluate drug delivery device technologies for their development programs. It combines supplier-confirmed device information, review by Kymanox subject matter experts, and searchable comparison tools in a single resource.
“Sponsors spend enormous time and effort trying to determine which device technologies are worth evaluating, and suppliers spend just as much effort trying to reach the right people. KymaBridge™ was built to solve both problems at once,” said Evan Edwards, Chief Executive Officer of Kymanox. “We’ve spent years building the device intelligence and verifying it the hard way, one program at a time. KymaBridge™ lets us put that same rigor in front of the whole industry, verified by our experts, so sponsors can trust what they’re seeing from day one.”
Solving a Scattered Selection Process
Selecting the right drug delivery device has traditionally required sponsors to piece together scattered technical documentation, informal supplier information, and time-consuming manual research. KymaBridge™ centralizes that information so sponsors can make early technology-screening decisions faster and with greater confidence.
The platform serves both sides of the device-selection process. Sponsors can search and compare a growing database of technologies spanning autoinjectors, pen injectors, on-body injectors, nasal devices, inhalers, and prefilled syringes across major device manufacturers. Device suppliers can verify the information about their own technology, and a paid KymaBridge™ Prime membership adds expanded profile management, usage reports, and more ways to showcase their products.
Verified by Design
KymaBridge™ is built on a simple premise: in a regulated industry, technology-matching data is only useful if it can be trusted. While AI can support discovery, Kymanox says device information still requires expert oversight to stay comprehensive, current, and verified. Every listing therefore begins with a review by Kymanox device and combination product experts, then invites the supplier to confirm the information directly.
“KymaBridge™ is the only place where device information is verified by both the supplier and an independent expert, and that means something to development program sponsors evaluating and actively looking for a device partner,” said Paul Jansen, Professional Engineer and Executive Advisor at Kymanox. “For suppliers with a Prime membership, they can go a step further and provide sponsors with a direct, credible channel into their active device development programs.”
Built on Two Decades of Combination Product Expertise
The platform draws on more than 20 years of Kymanox experience in drug-device combination products, including helping sponsors map drugs and biologics to device platforms and suppliers. Registration is now open at kymabridge.com, with complimentary sponsor access for qualifying Kymanox clients. Kymanox plans to continue expanding the platform’s offerings over the next year.
About Kymanox
Founded in 2004, Kymanox is a global life sciences consulting and professional services firm dedicated to accelerating the development and delivery of modern medicines and drug delivery systems. The company provides end-to-end solutions across engineering, technical operations, quality, regulatory, and manufacturing readiness, supporting clients in combination products, biologics, and advanced therapies. Kymanox is backed by WestView Capital Partners, a Boston-based growth equity firm.
